Rwanda is going to start locally manufacturing an assortment of pharmaceutical products and bridge the existing gaps in the supply chain – Taarifa reliably reports.
Apex Biotech Ltd, a locally registered company announced that they will produce more than 100 essential medicines that include prescription generic medicines and consumer healthcare products.
The company is scheduled on Wednesday (today) to launch construction of its production facility at the Kigali Special Economic Zone.
According to the proprietors, the entire investment is approximately worth more than $ 18 Million at completion of all its phases of development.
Biotech told Taarifa that the company will also be producing antiretroviral drugs, anti-Malaria drugs and Tuberculosis drugs and drugs for treating cardiovascular complications.
“We took consideration of drugs prescribed for common diseases including; Malaria, Tuberculosis, HIV/Aids and others. We will ensure steady supply,” said Dr Masroor Ehsan Executive Director, Apex Biotech Ltd.
Manufactured drugs will include generic medicines and consumer healthcare products.
Inquired about quality of the produced generic drugs, Dr Masroor said that the facility will also have a modern quality control centre to ensure all products leaving the production line fulfil acceptable global standards.
The company says will engage in the research, development, manufacturing, sourcing, marketing, and distribution of high-quality pharmaceutical products.
“We are a fully integrated company with in-house business development, manufacturing and regulatory compliance capabilities,” said Dr Masroor Ehsan.
Dr Masroor told Taarifa in an exclusive conversation that his company has large-scale production capacities, highly qualified production, and quality control staff, state of art GMP certified manufacturing facility combines to give a perfect environment to manufacture the highest quality products to our clients in a timely manner that is extremely cost competitive.
Rwanda has been importing more than 98% of healthcare commodities (including nearly 100% of pharmaceutical medicines).
During the 2015/2016 Financial Year, Rwanda spent FRW 74.2 billion to import medicines from foreign manufacturers.
Statistics by the Federation of East African Pharmaceutical Manufacturers (FEAPM) indicate that more than 70% of pharmaceutical drugs are imported from Asia and Europe.
However, the regional pharmaceutical body agreed in August last year that by 2027 phamaceutical imports to the region will reduced from 70% to less than 50%.
Regional member states are also required to procure at least 50% of pharmaceutical products from local manufacturers.